Please use this identifier to cite or link to this item:
Title: Impact of 18F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative 131I whole body scan and elevated serum thyroglobulin.
Austin Authors: Boktor, Raef R;Lee, Sze Ting ;Berlangieri, Salvatore U ;Scott, Andrew M 
Affiliation: Olivia Newton-John Cancer Research Institute
Molecular Imaging and Therapy
Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia
School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia
Issue Date: 2022
Publication information: Asia Oceania Journal of Nuclear Medicine & Biology 2022; 10(1): 20-27
Abstract: 18F-FDG PET/CT is increasingly performed in patients with differen-tiated thyroid cancer. The aim of this study was to assess the clinical impact of 18F-FDG PET/CT on the management of patients with differentiated thyroid carcinoma who had elevated serum thyroglobulin (Tg) and negative 131I whole body scan (WBS). 67 patients with differentiated thyroid carcinoma were included in this study. The findings of 18F-FDG PET/CT imaging were compared with histo-pathology, follow up imaging, or clinical follow-up results. The diagnostic accuracy of 18F-FDG PET/CT was evaluated for the entire patient group and for those patients with stimulated serum thyroglobulin levels of less than 5, 5-10, and more than 10 pmol/L as well as for local recurrences and metastases sites. The impact of 18F-FDG PET/CT on therapeutic management was also evaluated. 30/67 patients had positive findings on 18F-FDG PET/CT; 28 were true-positive and 2 were false-positive. 18F-FDG PET/CT results were true-negative in 36 patients and false-negative in 1 patient. The overall sensitivity, specificity, accuracy, PPV and NPV of 18F-FDG PET/CT were, 96.5%, 94.5%, 95.5%, 93.3%, and 97.2% respectively. Positive 18F-FDG PET/CT findings were directly correlated with stimulated serum thyroglobulin levels, 7.1% had Tg between 5-10, and 92.9% had Tg greater than 10 pmol/L. 18F-FDG PET/CT had a high or moderate impact on treatment management in 28 (41.8%) of patients. 18F-FDG PET/CT is able to improve diagnostic accuracy and have management impact in a therapeutically relevant way in patients with differentiated thyroid carcinoma who present with rising thyroglobulin level, negative 131I WBS, and clinical suspicion of recurrent disease.
DOI: 10.22038/AOJNMB.2021.58276.1406
ORCID: 0000-0003-4861-619X
Journal: Asia Oceania Journal of Nuclear Medicine & Biology
PubMed URL: 35083346
PubMed URL:
ISSN: 2322-5718
Type: Journal Article
Subjects: 131I
Thyroid carcinoma
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.